Hansa Biopharma and German payer head association agree on reimbursement price for Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

/PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announces...

Related Keywords

Sweden ,Germany ,Stockholm ,Netherlands ,Finland ,France ,Jordan ,Greece ,German ,Hansa Biopharma ,Prnewswire Hansa Biopharma ,Klaus Sindahl ,Katja Margell ,National Association Of Statutory Health Insurance Funds ,European Union ,European Medicines Agency ,European Medicines Agency Ema Priority ,Head Of Corporate Communications ,National Association ,Statutory Health Insurance Funds ,Nasdaq Stockholm ,Medicines Market Reorganization Act ,Human Leukocyte Antigens ,European Marketing Authorization ,End Stage Renal Disease ,Product Characteristicsfound ,Product Characteristics ,Englj Med ,Hansa Biopharma Ab ,